Zhejiang Orient Gene Biotech Co.,Ltd

688298

CNE100003RM8

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
27.76 ^CNY	+1.87%		+5.47%	-22.37%

Apr. 23	Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products	MT
Feb. 28	Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.

February 06, 2024

The Board of Directors of Zhejiang Orient Gene Biotech Co.,Ltd has authorized a buyback plan on February 7, 2024.

Latest news about Zhejiang Orient Gene Biotech Co.,Ltd

Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products	Apr. 23	MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Zhejiang Orient Gene Biotech Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	Feb. 07	CI
Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.	Feb. 06	CI
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License	Jan. 08	MT
Zhejiang Orient Gene Biotech Co.,Ltd(SHSE:688298) dropped from Shanghai Stock Exchange Health Care Sector Index	Dec. 08	CI
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents	23-07-13	MT
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman	23-06-01	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang Orient Gene Registers Two Medical Devices in EU, US	23-03-24	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
IN BRIEF: Omega Diagnostics receives CD4 deferred consideration	22-11-25	AN
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Omega Diagnostics Up 16% With Sale Of Loss-Making CD4 Business	22-08-03	MT
ZXBio, Inc. announced that it has received $3.1 million in funding from Zhejiang Orient Gene Biotech Co., Ltd.	22-06-07	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Omega Diagnostics Shares Plunge on $1.4 Million Sale of Loss-making Business to Chinese Biotech	22-02-11	MT
MSCI to Add Gree, Three Gorges Renewables, Others to China Indices	22-02-10	MT
China Detects First Case of COVID-19 Omicron Strain	21-12-13	MT
Chinese COVID-19 Tests Can Detect Omicron Variant, Manufacturers Say	21-11-29	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI

Chart Zhejiang Orient Gene Biotech Co.,Ltd

Duration

Period

Chart Zhejiang Orient Gene Biotech Co.,Ltd

More charts

Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
ZHEJIANG ORIENT GENE BIOTECH CO.,LTD	-22.37%	772M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances